[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-urticaria\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-urticaria":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100611114","comparing-standard-dose-and-high-dose-cetirizine-for-acute-urticaria-100611114",false,"NCT07236372","Comparing Standard-Dose and High-Dose Cetirizine for Acute Urticaria","Comparative Efficacy of Standard-Dose Versus Updosed Cetirizine in Acute Urticaria: A Randomized Controlled Trial","CURE-AU","Inclusion Criteria:\n\n* Adults aged 18 to 60 years\n* Clinical diagnosis of acute urticaria made by a physician\n* Onset of new wheals within the past 24 hours\n* Able and willing to comply with study procedures, complete symptom diaries, and attend follow-up visits\n* Provides written informed consent prior to participation\n\nExclusion Criteria:\n\n* Use of systemic corticosteroids within the past 5 days\n* Use of immunosuppressive medications within the past 5 days\n* Clinical signs of anaphylaxis, including respiratory distress, hypotension, abdominal pain, or acute laryngeal swelling\n* Presence of angioedema without wheals\n* Known diagnosis of chronic urticaria\n* Known severe renal impairment (creatinine clearance \\\u003C10 mL\u002Fmin), heart failure (ejection fraction \\\u003C40%), or hepatic failure\n* Other skin conditions that may interfere with assessment (e.g., atopic dermatitis, eczema, bullous pemphigoid, AGEP)\n* Use of ACE inhibitors or ARBs within the past 5 days\n* Known allergy or hypersensitivity to cetirizine or components of the study medication\n* Pregnancy or breastfeeding\n* Known diabetes mellitus\n* History of gastrointestinal ulcer disease\n* Any condition that, in the investigator's judgment, would interfere with study participation or safety\n* Declines to provide informed consent","ALL","18 Years","60 Years",{"count":21,"type":22},140,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn whether a higher dose of cetirizine works better than the standard dose to relieve symptoms of acute urticaria (hives) in adults. The study also aims to learn about the safety of taking a higher dose for a short period of time. The main questions the study aims to answer are:\n\n1. Does the higher dose of cetirizine help people with acute urticaria improve faster than the standard dose?\n2. What side effects do participants experience when taking the higher dose?\n\nResearchers will compare two groups:\n\none group taking the standard dose of cetirizine (10 mg per day) and another group taking a higher dose (40 mg per day). This will help researchers understand which dose works better and whether the higher dose is safe.\n\nParticipants will:\n\nTake the assigned study medication for 7 days Record their daily symptoms, including itch and hive severity Return for follow-up visits on Day 3, Day 7, and Week 6 Have blood tests to check liver and kidney function before and after treatment\n\nThis study may help improve treatment options for people with acute urticaria and reduce the need for unnecessary steroid use.",[28],"Acute Urticaria",[28,30,31,32,33,34],"Updosed Cetirizine","High-Dose Antihistamine","Standard-Dose Cetirizine","Second-Generation Antihistamine","Randomized Controlled Trial","RECRUITING","2026-05-31",{"date":38,"type":39},"2026-06-03","ACTUAL",{"date":41,"type":39},"2025-11-15",{"date":43,"type":22},"2026-10",{"name":45,"class":46},"University of Phayao","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":47},"100579090","phase-3-phase-iii-clinical-study-of-cetirizine-hydrochloride-injection-in-treatment-of-acute-urticaria-100579090","NCT06819774","Phase III Clinical Study of Cetirizine Hydrochloride Injection in Treatment of Acute Urticaria","Efficacy and Safety of Cetirizine Hydrochloride Injection in the Treatment of Acute Urticaria: a Randomized, Double-blind, Positive Controlled, Multicenter Phase III Clinical Study","Phase III","Inclusion Criteria:\n\n1. Age range: 18 - 65 years old (inclusive of the threshold value), gender not limited;\n2. Diagnosed with acute urticaria (the definition of acute urticaria: spontaneous wheals and\u002For angioedema attacks ≤ 6 weeks);\n3. At screening，the severity score of pruritus of the patient was ≥ 1 point ;\n4. At screening，the degree score of wheals\u002Ferythema of the patient assessed by the investigator was ≥ 1 point ;\n5. Be willing and able to give informed consent.\n\nExclusion Criteria:\n\n1. Patients in whom an antihistamine are contraindicated (such as those with angle-closure glaucoma, symptomatic benign prostatic hyperplasia, etc.);\n2. Patients who used H1 antagonists (such as diphenhydramine, cetirizine, loratadine, fexofenadine, levocetirizine, desloratadine, etc.) within 2 hours before randomization;\n3. Patients who used H2 antagonists (such as cimetidine, ranitidine, famotidine, roxatidine, etc.) within 2 hours before randomization;\n4. Patients who used doxepin within 2 hours before randomization;\n5. Patients who received steroid hormone treatment for acute allergic reactions within 4 hours before randomization;\n6. Patients who used epinephrine within 20 minutes before randomization;\n7. Patients who are known to be allergic to hydroxyzine, cetirizine, levocetirizine, diphenhydramine;\n8. Pregnant or lactating women; or those who have a pregnancy plan or plan to donate sperm\u002Feggs from the screening day to the end of medication within 1 month; or those who are unwilling to take one or more contraceptive measures from the screening day to the end of medication within 1 month;\n9. Patients with urticarial drug eruption;\n10. Patients with acute urticaria who have concurrent symptoms such as laryngeal edema, allergic asthma, anaphylactic shock during screening;\n11. Patients with urticarial vasculitis, hereditary angioedema, antihistamine-resistant urticaria or skin diseases that interfere with the evaluation of treatment efficacy during screening;\n12. Patients with a history of immunodeficiency;\n13. Patients with other major medical conditions (such as blood diseases, cardiovascular and cerebrovascular diseases, liver diseases, kidney diseases, etc.) or mental disorders and judged by the investigator to be unsuitable to participate in this study;\n14. Patients who are concurrently using P-glycoprotein inhibitors (such as cyclosporine, itraconazole, dronedarone, amiodarone, quinidine, verapamil, etc.) during screening;\n15. Patients who participated in other clinical trials within 3 months before screening (excluding those who only participated in the screening of the clinical trial but did not use the trial drugs or devices);\n16. Patients with acute urticaria accompanied by fever during screening;\n17. Patients engaged in dangerous jobs such as driving, high-altitude work, mechanical operation, etc., and cannot stop within 48 hours after medication;\n18. Other various situations.","65 Years",{"count":58,"type":22},284,[60],"PHASE3","The objective of this study was to evaluate the efficacy and safety of cetirizine hydrochloride injection in the treatment of acute urticaria.The participants were randomized to receive cetirizine hydrochloride or diphenhydramine hydrochloride.",[28],[64,65],"Cetirizine hydrochloride injection","acute urticatia","2025-02-06",{"date":68,"type":39},"2025-02-11",{"date":70,"type":39},"2024-04-22",{"date":72,"type":22},"2025-08",{"name":74,"class":75},"Shandong New Time Pharmaceutical Co., LTD","INDUSTRY"]